Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (51-60 of 323) with videos related to

Pageof 33
Sort By:
European Urology|September 25, 2016
Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3Marcus V Cronauer, Axel S Merseburger, M Raschid Hoda
Current Urology Reports|February 19, 2015
Preoperative and modifiable factors to lower postoperative complications after radical cystectomyMarie C Hupe, Mario W Kramer, Axel S Merseburger
European Urology|October 8, 2013
No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy settingChristoph A von Klot, Markus A Kuczyk, Axel S Merseburger
Therapeutic Advances in Urology|February 3, 2015
An update on enzalutamide in the treatment of prostate cancerAxel S Merseburger, Gabriel P Haas, Christoph-A von Klot
Aktuelle Urologie|July 22, 2025
Friederike Praus, Axel S Merseburger, Daniar Osmonov, et al.
Molecular and Clinical Oncology|June 18, 2016
Novel therapeutic options for second-line therapy in metastatic renal cell carcinomaC A VON Klot, Axel S Merseburger, Markus A Kuczyk
Scandinavian Journal of Urology and Nephrology|October 2, 2007
Tissue microarrays in clinical urology--technical considerationsMario W Kramer, Axel S Merseburger, Jorg Hennenlotter, et al.
Expert Review of Anticancer Therapy|June 22, 2012
Second-line systemic therapy for the treatment of metastatic renal cell cancerStephan Kruck, Jens Bedke, Markus A Kuczyk, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
Expert Review of Anticancer Therapy|October 16, 2009
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancerAxel S Merseburger, Annika Simon, Sandra Waalkes, et al.
Pageof 33

Showing results (51-60 of 323) with videos related to

Sort By:
Pageof 33
European Urology|September 25, 2016
Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3Marcus V Cronauer, Axel S Merseburger, M Raschid Hoda
Current Urology Reports|February 19, 2015
Preoperative and modifiable factors to lower postoperative complications after radical cystectomyMarie C Hupe, Mario W Kramer, Axel S Merseburger
European Urology|October 8, 2013
No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy settingChristoph A von Klot, Markus A Kuczyk, Axel S Merseburger
Therapeutic Advances in Urology|February 3, 2015
An update on enzalutamide in the treatment of prostate cancerAxel S Merseburger, Gabriel P Haas, Christoph-A von Klot
Aktuelle Urologie|July 22, 2025
Friederike Praus, Axel S Merseburger, Daniar Osmonov, et al.
Molecular and Clinical Oncology|June 18, 2016
Novel therapeutic options for second-line therapy in metastatic renal cell carcinomaC A VON Klot, Axel S Merseburger, Markus A Kuczyk
Scandinavian Journal of Urology and Nephrology|October 2, 2007
Tissue microarrays in clinical urology--technical considerationsMario W Kramer, Axel S Merseburger, Jorg Hennenlotter, et al.
Expert Review of Anticancer Therapy|June 22, 2012
Second-line systemic therapy for the treatment of metastatic renal cell cancerStephan Kruck, Jens Bedke, Markus A Kuczyk, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
Expert Review of Anticancer Therapy|October 16, 2009
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancerAxel S Merseburger, Annika Simon, Sandra Waalkes, et al.
Pageof 33